Neurology Panel
The Neurology Genetics Panel is a targeted Next-Generation Sequencing (NGS) assay engineered to comprehensively profile germline mutations in genes governing central and peripheral nervous system development, neuronal conduction, myelination, and neurodegenerative pathways. Neurological disorders encompass a vast, clinically overlapping spectrum including neuromuscular diseases, refractory epilepsies, movement disorders, early-onset dementias, and hereditary ataxias. This panel resolves diagnostic complexity in patients with atypical or overlapping neurogenetic presentations, enabling accurate molecular diagnosis, genotype-targeted therapeutics, prognostic stratification, and family risk management.
Key Features & Advantages
- Definitive Molecular Diagnosis: Resolves phenotypic heterogeneity and diagnostic overlap across complex neurogenetic conditions (e.g., distinguishing between diverse hereditary ataxias or spastic paraplegias).
- Enables Targeted & Gene-Specific Therapies: Facilitates early access to disease-modifying therapies, such as gene replacement for SMA, enzyme replacement in metabolic storage diseases, or targeted anti-seizure protocols in monogenic epilepsies.
- Minimizes Invasive Diagnostic Procedures: Reduces the reliance on invasive diagnostic steps, such as muscle/nerve biopsies and recurrent lumbar punctures.
- Predictive Prognostication & Systemic Management: Forecasts disease trajectory and anticipated systemic involvement (e.g., cardiorespiratory complications), allowing proactive, multidisciplinary care.
Neurology NGS Panel vs. Conventional Neurological Diagnostics
| Feature | Neurology Genetics Panel (NGS) | Standard Neurological Diagnostics (EMG, EEG, MRI, Muscle Biopsy) |
| Diagnostic Scope | Genes encoding neuronal, muscular, and myelination proteins | Neural electrical activity, conduction velocity, and structural imaging |
| Etiological Resolution | High (Pinpoints the underlying molecular mechanism and causative gene) | Phenotypic (Detects functional impairment or tissue lesion, not root cause) |
| Invasiveness & Risk | Non-invasive (Peripheral blood or saliva sample) | Moderate/High (Invasive muscle/nerve biopsies carries surgical risks) |
| Targeted Therapeutics | Informs gene therapies, specific enzyme replacements, and precision drugs | Directs generalized symptomatic and supportive management protocols |
| Familial Risk Mapping | Absolute (Defines autosomal dominant/recessive, X-linked, or mitochondrial inheritance) | None |
Key Applications
- Neuromuscular Disorders: Muscular Dystrophies (Duchenne/Becker, LGMD), Spinal Muscular Atrophy (SMA), Charcot-Marie-Tooth disease (CMT), and Congenital Myopathies.
- Epilepsy & Developmental Encephalopathies: Refractory pediatric epilepsies, Dravet Syndrome, CDKL5 deficiency disorder, and early infantile epileptic encephalopathies.
- Movement Disorders & Hereditary Ataxias: Spinocerebellar Ataxias (SCA), Friedreich Ataxia, Hereditary Spastic Paraplegia (HSP), Familial Parkinson’s Disease, and Dystonias.
- Neurodegenerative Diseases & Dementias: Early-Onset Alzheimer’s Disease, Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementia (FTD).
- Neurocutaneous Syndromes: Neurofibromatosis Type 1 and 2 (NF1, NF2) and Tuberous Sclerosis Complex (TSC).
The Nucleus Genetics Advantage: Combining ultra-deep NGS target panels aligned with AAN and EFNS guidelines, advanced bioinformatic pipelines, and multidisciplinary curation by medical geneticists and neurologists, we convert complex neurogenomic data into actionable clinical insights.
Get Information About This Service
Our expert team is ready to answer your questions and offer tailored solutions.
Contact Form →